




PHARMACEUTICAL 2021

Skye Bioscience Inc.
Rank 358 of 402





PHARMACEUTICAL 2021

Skype Bioscience Inc.
Rank 358 of 402

The relative strengths and weaknesses of Skype Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skype Bioscience Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 17% points. The greatest weakness of Skype Bioscience Inc. is the variable Net Income, reducing the Economic Capital Ratio by 171% points.

The company's Economic Capital Ratio, given in the ranking table, is -236%, being 284% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	2,664
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	787
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1.6
Other Liabilities	1,434
Other Net Income	-270
Other Revenues	0
Property and Equipment	7.3
Research and Development	1,944
Selling, General and Administrative Expense	4,345

Output Variable	Value in 1000 USD
Assets	2,672
Liabilities	2,221
Expenses	6,291
Revenues	0
Stockholders Equity	451
Net Income	-6,561
Comprehensive Net Income	-6,561
Economic Capital Ratio	-236%